Sangamo Therapeutics Profit Margin

The latest profit margin for SGMO is -356.89% as of March 2026. That compares with -124.61% in the prior-year period — down 186.4% year over year. That is below the Healthcare sector average of 13.76%. Investors often review this figure alongside Sangamo Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SGMO's profit margin moved from -124.61% to -356.89% — a 186.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Sangamo Therapeutics's valuation or profitability profile.

Against Healthcare companies, SGMO currently prints -356.89% for profit margin, while the sector average sits near 13.76%. That is roughly 2693.6% below the sector mean. Large gaps often invite a closer look at Sangamo Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Sangamo Therapeutics converts resources into returns. At -356.89%, SGMO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -124.61% in the prior-year period — down 186.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SGMO's profit margin (-356.89%), review year-over-year change from -124.61%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.